

Likang research brochure — attributed source

立康研发折页 — 厂商原始资料

Both original brochure pages follow this editorial cover. Research products are not an offer of available treatment.

本说明后附原折页两页。研发产品不代表可预约治疗项目。

These are supplied manufacturer materials, not independently validated Uwell clinical guidance. Claims and dates in the sources may conflict. In particular, the FDA and Lecheng dates in the English brochure differ from the Chinese introduction; neither disputed date is endorsed here.

以下为所提供的厂商资料，不是优健云独立验证的临床指导。原资料中的陈述与日期可能存在冲突，尤其英文折页的FDA及乐城相关日期与中文介绍不一致，本文件不认可其中任一争议日期。

Confirm current access, eligibility, sample handling and any treatment instructions directly with the receiving clinical team. Do not use this document to change medication, arrange sample shipment or replace standard care. Uwell coordinates enquiries and does not collect medical fees.

当前项目路径、适用条件、样本处理及治疗要求须由接诊临床团队确认。请勿据此自行调整用药、寄送样本或替代标准治疗。优健云协助咨询协调，不收取医疗费用。

Source / 来源：LIKANG-trifold.pdf

Prepared / 整理：2026-09-09 / uwellcloud.com/program-lk101.html

LK101

Personalized Neoantigen mRNA-DC Vaccine

01

PATIENT-SPECIFIC

Neoantigens are identified based on each patient's tumor.

02

PERSONALIZED mRNA

Selected neoantigen sequences are encoded in a personalized mRNA construct.

03

AUTOLOGOUS DC DELIVERY

Personalized neoantigen mRNA is delivered through autologous dendritic cells.

04

TARGETED IMMUNE RESPONSE

Designed to induce neoantigen-specific T-cell responses.



Mar 2023

NMPA IND clearance.



Feb 2025

U.S. FDA IND clearance.

LK201

Personalized Multi-Target Neoantigen-Specific T-Cell Therapy

01

MULTI-TARGET

Targets up to 30 neoantigens to help limit tumor escape.

02

BROAD T-CELL RESPONSE

Includes both CD4+ and CD8+ neoantigen-specific T cells.

03

PERIPHERAL BLOOD-DERIVED

Uses peripheral blood without requiring tumor tissue collection for manufacturing.

04

NON-TRANSGENIC

No lentiviral transduction required.

EXPANDING PIPELINE



LK301

Shared-Antigen TCR-T Program
(Mutation-Positive Tumors)



LK302

Shared-Antigen TCR-T Program
(Antigen-Expressing Tumors)



LK401

Personalized Neoantigen
TCR-T Program



**A PATIENT.
A UNIQUE PROFILE.
A PERSONALIZED THERAPY.**
Personalized Immunotherapy, Powered by AI.

WHO WE ARE

Likang Life Sciences is a clinical-stage biotechnology company pioneering personalized cancer immunotherapies powered by AI and bioinformatics.

We integrate neoantigen discovery with mRNA and cell therapy platforms to develop therapies tailored to each patient’s tumor.



LNEA

AI-Powered Neoantigen
Discovery Platform



LK101

Personalized
Neoantigen Vaccine



LK201

Personalized
T-Cell Therapy


FROM ONE PROFILE TO ONE TAILORED THERAPY

Every tumor is unique.
Personalized immunotherapy begins with understanding its unique biology.

WHAT ARE NEOANTIGENS?

Neoantigens are tumor-specific protein fragments arising from mutations and absent from normal tissues.

Because they may be recognized as “non-self” by the immune system, they can serve as targets for personalized immunotherapy.



KEY MILESTONES

2017

Likang Life Sciences Founded
Beijing, China

2018

LNEA Platform Established
Proprietary AI-powered platform for tumor neoantigen analysis

MAR 2023

China NMPA IND Clearance
LK101

FEB 2025

U.S. FDA IND Clearance
LK101

APR 2025

Hainan Boao Lecheng Translational Application Approval
Covering 11 solid tumor indications



GLOBAL COLLABORATION

Partnering with leading healthcare systems, research institutions and governments to advance clinical development and personalized cancer immunotherapy.

✉ operations@likanglife.com

🌐 www.likanglife.com